Zobrazeno 1 - 10
of 38
pro vyhledávání: '"K.N. Slaughter"'
Autor:
Wade, K.N. Slaughter, Brady, M.F., Thai, T., Wang, Y., Zheng, B., Salani, R., Tewari, K.S., Gray, H.J., Bakkum-Gamez, J.N., Burger, R.A., Moore, K.N., Bookman, M.A.
Publikováno v:
In Gynecologic Oncology October 2019 155(1):69-74
Autor:
Ritu Salani, Krishnansu S. Tewari, Mark F. Brady, Robert A. Burger, Jamie N. Bakkum-Gamez, Y. Wang, K.N. Slaughter Wade, Michael A. Bookman, Heidi J. Gray, Bin Zheng, Theresa C. Thai, Kathleen N. Moore
Publikováno v:
Gynecol Oncol
Objective Adiposity has been hypothesized to interfere with the activity of bevacizumab (BEV), an anti-angiogenic agent. Measurements of adiposity, BMI, surface fat area (SFA), and visceral fat area (VFA) were investigated as prognostic of oncologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78dfe6b224783ab5f16876de20dd5419
https://doi.org/10.1016/j.ygyno.2019.07.020
https://doi.org/10.1016/j.ygyno.2019.07.020
Autor:
Ana I. Tergas, Sean C. Dowdy, Kimberly Levinson, Micael Lopez, Kara Long Roche, Robert E. Bristow, Stephanie Ricci, Kathleen N. Moore, Melissa Gerardi Fairbairn, K.N. Slaughter, Amanda N. Fader
Publikováno v:
Gynecologic Oncology Reports
Gynecologic Oncology Reports, Vol 22, Iss C, Pp 100-104 (2017)
Gynecologic Oncology Reports, Vol 22, Iss C, Pp 100-104 (2017)
A recent ASCO workforce study projects a significant shortage of oncologists in the U.S. by 2020, especially in rural/underserved (R/US) areas. The current study aim was to determine the patterns of distribution of U.S. gynecologic oncologists (GO) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d75aadc96fb81f0f7200ac421a332f9
https://escholarship.org/uc/item/8ng916jj
https://escholarship.org/uc/item/8ng916jj
Autor:
L. Perry, D. Scott McMeekin, E. Bishop, K.N. Slaughter, Elizabeth K. Nugent, Kathleen N. Moore
Publikováno v:
Gynecologic Oncology. 132:231-235
Objectives Previous reviews of phase I clinical trials report limited response rates. Development of novel biologic agents and trials designs have increased these rates. A contemporary appraisal of phase I clinical trials in gynecologic malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bce01507aed0a4ac22d436310c96834
https://doi.org/10.1016/j.ygyno.2013.09.003
https://doi.org/10.1016/j.ygyno.2013.09.003
Autor:
Y. Wang, Ritu Salani, Krishnansu S. Tewari, B. Zheng, Heidi J. Gray, Jamie N. Bakkum-Gamez, Mark F. Brady, Michael A. Bookman, Theresa C. Thai, Robert A. Burger, Kathleen N. Moore, K.N. Slaughter
Publikováno v:
Gynecologic Oncology. 145:32-33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e324559b85ceaad1009fd47083e91bc
https://doi.org/10.1016/j.ygyno.2017.03.086
https://doi.org/10.1016/j.ygyno.2017.03.086
Publikováno v:
Oncotarget
// Shailendra Kumar Dhar Dwivedi 1 , Scott D. McMeekin 1 , Katrina Slaughter 1 and Resham Bhattacharya 1 1 Department of Obstetrics and Gynecology, Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma, USA Correspondence t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::347580028d5744aec42ab764c11b5de9
https://pubmed.ncbi.nlm.nih.gov/25918253
https://pubmed.ncbi.nlm.nih.gov/25918253
Publikováno v:
Current Oncology Reports. 16
The investigation of anti-angiogenic agents and dose-dense paclitaxel therapy in epithelial ovarian cancer is an active area of research. To date several phase III trials have shown both approaches to be effective strategies for the frontline treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82d9c14a1abfa4b185b790a982dfde55
https://doi.org/10.1007/s11912-014-0412-2
https://doi.org/10.1007/s11912-014-0412-2
Autor:
K.N. Slaughter, Doris M. Benbrook, Scott McMeekin, Blake Scott, Kathleen N. Moore, Imoh I. Okon
Publikováno v:
Brachytherapy. 14:100-101
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcaa2a240ae9e558a655190988a7668a
https://doi.org/10.1016/j.brachy.2014.08.025
https://doi.org/10.1016/j.brachy.2014.08.025
Publikováno v:
Gynecologic Oncology. 135:394-395
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c66f40f46bf2f284a01b7d9118ef987
https://doi.org/10.1016/j.ygyno.2014.07.040
https://doi.org/10.1016/j.ygyno.2014.07.040
Autor:
D.S. McMeekin, Kathleen N. Moore, L. Perry, Camille C. Gunderson, R. Farrell, K.N. Slaughter, Kai Ding, J.K. Lauer
Publikováno v:
Gynecologic Oncology. 133:49-50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b31d46fc7c79cf7c1954bbf3dc45d23c
https://doi.org/10.1016/j.ygyno.2014.03.140
https://doi.org/10.1016/j.ygyno.2014.03.140